Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Standard care

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,491 result(s) found for: Standard care. Displaying page 86 of 325.
    «« First « Previous 82  83  84  85  86  87  88  89  90  Next» Last»»
    EudraCT Number: 2021-003815-25 Sponsor Protocol Number: CP0101-CLL Start Date*: 2022-02-21
    Sponsor Name:CellPoint B.V.
    Full Title: A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (C...
    Medical condition: relapsed / refractory Chronic Lymphocytic Leukemia relapsed / refractory Small Lymphocytic Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003296-18 Sponsor Protocol Number: LDX0119 Start Date*: 2020-12-30
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Effect of oral ladarixin 400 mg twice a day on insulin sensitivity. A phase 2, randomized, double-blind, placebo-controlled explorative study in obese patients with pre-diabetes eligible to bariatr...
    Medical condition: Obesity and pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10036481 Pre-diabetes LLT
    20.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003617-17 Sponsor Protocol Number: NCT03348735 Start Date*: 2018-12-03
    Sponsor Name:Antwerp University Hospital (UZA)
    Full Title: Efficacy, patient acceptability and safety of topical treatment versus systemic treatment: a randomized, multicenter, comparative pragmatic trial in adult patients suffering from diverse localized ...
    Medical condition: Patients suffering from localized neuropathic pain (LNP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003787-24 Sponsor Protocol Number: PM-CARE-PNRR-MAD-2022-12375905 Start Date*: 2023-04-20
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (Single arm, multicenter phase II study investigating the efficacy and safety...
    Medical condition: Unresectable intrahepatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003070-23 Sponsor Protocol Number: CLITRETVER Start Date*: 2023-01-27
    Sponsor Name:Verisfield S.M.S.A.
    Full Title: A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acn...
    Medical condition: Acne Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003282-98 Sponsor Protocol Number: OLT1177-07 Start Date*: 2018-03-07
    Sponsor Name:Olatec Therapeutics LLC
    Full Title: A Pilot, Open-Label, Phase 2, Single-Center, Repeat Dose, Proof-of-Concept Safety, Pharmacodynamics and Efficacy Study of Orally Administered Dapansutrile Capsules in Subjects with Schnitzler’s Syn...
    Medical condition: Schnitzler's syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10062908 Schnitzler's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003415-29 Sponsor Protocol Number: 2.0 Start Date*: 2023-04-03
    Sponsor Name:Leiden University Medical Centre
    Full Title: The effect of antenatal acetaminophen administration on breathing effort of premature infants at birth: a pilot study
    Medical condition: Pregnant women expected to deliver between 24 and 30 weeks' gestation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10033762 Paracetamol LLT
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006914-62 Sponsor Protocol Number: BAY 43-9006 / 13266 Start Date*: 2009-04-23
    Sponsor Name:Bayer HealthCare AG, 51368 Leverkusen, Germany
    Full Title: A Phase III, multi-center, placebo–controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2...
    Medical condition: Non-small cell lung carcinoma in patients with predominantly non-squamous cell carcinoma histology
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029515 Non-small cell lung cancer recurrent PT
    9.1 10059515 Non-small cell lung cancer metastatic PT
    9.1 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Completed) AT (Completed) SE (Completed) ES (Completed) FR (Completed) BG (Completed) HU (Completed) GR (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004183-21 Sponsor Protocol Number: IP-001-18 Start Date*: 2022-08-19
    Sponsor Name:Iperboreal Pharma Srl
    Full Title: A Study to Evaluate the EffIcacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis
    Medical condition: End-Stage Renal Disease (ESRD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038359 - Renal and urinary disorders 10077512 End stage renal disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004936-36 Sponsor Protocol Number: CLL13 Start Date*: 2016-11-08
    Sponsor Name:University of Cologne
    Full Title: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) ve...
    Medical condition: fit patients with previously untreated CLL without del(17p) or TP53 mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) AT (Completed) FI (Completed) BE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003799-22 Sponsor Protocol Number: CVT-301-005 Start Date*: 2015-02-11
    Sponsor Name:Civitas Therapeutics, Inc.
    Full Title: A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Obser...
    Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10034007 Parkinson's disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005906-32 Sponsor Protocol Number: WAKE-UP Start Date*: 2012-09-24
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial
    Medical condition: Patients with acute ischemic stroke proven by MRI and unknown time from symptom onset which otherwise fulfil the approval criteria for intravenous thrombolysis in acute stroke
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003721-22 Sponsor Protocol Number: A4091058 Start Date*: 2016-01-14
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP ...
    Medical condition: Osteoarthritis of the hip or knee
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10023476 Knee osteoarthritis LLT
    20.0 100000004859 10020108 Hips osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed) LT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005053-25 Sponsor Protocol Number: TRAM Start Date*: Information not available in EudraCT
    Sponsor Name:Institute of Mother and Child
    Full Title: Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment.
    Medical condition: histiocytic cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078782 Langerhans cell sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060801 Erdheim-Chester disease PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063397 Rosai-Dorfman syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000874-92 Sponsor Protocol Number: LUM-201-01 Start Date*: 2021-03-22
    Sponsor Name:Lumos Pharma, Inc.
    Full Title: A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficie...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000104-15 Sponsor Protocol Number: CCS1477-02 Start Date*: 2021-07-29
    Sponsor Name:CellCentric Ltd
    Full Title: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies.
    Medical condition: Acute Myeloid Leukaemia (AML)/high-risk Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Non-Hodgkin Lymphoma(NHL).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005120-16 Sponsor Protocol Number: 62638 Start Date*: 2018-11-02
    Sponsor Name:Amsterdam UMC, Location VUmc
    Full Title: Ulipristal versus standard surgical treatment in symptomatic uterine fibroids
    Medical condition: Uterine fibroids are very common during reproductive years in women. Minimally invasive treatments are emerging. Myomectomy is the gold standard, preferably laparoscpically, because it removes the ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10046784 Uterine fibroids LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004052-11 Sponsor Protocol Number: UC-HNG/1909 Start Date*: 2020-07-08
    Sponsor Name:UNICANCER
    Full Title: A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma
    Medical condition: Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of primary surgery. Patients with a di...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041824 Squamous cell carcinoma of esophagus LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041859 Squamous cell carcinoma of the oral cavity stage 0 LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041860 Squamous cell carcinoma of the oral cavity stage I LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041861 Squamous cell carcinoma of the oral cavity stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041862 Squamous cell carcinoma of the oral cavity stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041863 Squamous cell carcinoma of the oral cavity stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031113 Oropharyngeal squamous cell carcinoma recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031114 Oropharyngeal squamous cell carcinoma stage 0 LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031115 Oropharyngeal squamous cell carcinoma stage I LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021052 Hypopharyngeal squamous cell carcinoma recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021053 Hypopharyngeal squamous cell carcinoma stage 0 LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021055 Hypopharyngeal squamous cell carcinoma stage II LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021054 Hypopharyngeal squamous cell carcinoma stage I LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041854 Squamous cell carcinoma of the hypopharynx stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041853 Squamous cell carcinoma of the hypopharynx stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041855 Squamous cell carcinoma of the hypopharynx stage IV LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023856 Laryngeal squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000372-95 Sponsor Protocol Number: ALX0061-C204 Start Date*: 2015-08-20
    Sponsor Name:Ablynx N.V.
    Full Title: A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate ...
    Medical condition: Moderate to Severe Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017968 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) PT (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005554-23 Sponsor Protocol Number: 1199-0378 Start Date*: 2021-11-24
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: An open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 2 years, in children and adolescents with clinically significant fibrosi...
    Medical condition: Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066393 Respiratory bronchiolitis-associated interstitial lung disease LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Prematurely Ended) BE (Trial now transitioned) NL (Ongoing) GR (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) FI (Completed) DK (Ongoing) IT (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 82  83  84  85  86  87  88  89  90  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 19:36:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA